Education
About Us
Working with TipRanks
Follow Us
Allogene Therapeutics Inc (ALLO)
NASDAQ:ALLO
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 0.00 | $ 22.00K | $ 95.00K | $ 156.00K | $ 114.09M |
| Gross Profit | $ -12.36M | $ 22.00K | $ 95.00K | $ -14.14M | $ 114.09M |
| Operating Income | $ -206.93M | $ -273.20M | $ -327.74M | $ -335.54M | $ -180.19M |
| EBITDA | $ -194.57M | $ -243.33M | $ -313.07M | $ -321.24M | $ -169.74M |
| Net Income | $ -190.89M | $ -257.59M | $ -327.26M | $ -340.41M | $ -182.05M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 250.21M | $ 292.48M | $ 448.70M | $ 517.32M | $ 457.30M |
| Total Assets | $ 415.90M | $ 548.71M | $ 642.84M | $ 821.58M | $ 1.05B |
| Total Debt | $ 75.05M | $ 90.76M | $ 95.12M | $ 101.12M | $ 73.13M |
| Net Debt | $ 23.36M | $ 15.54M | $ 11.97M | $ 39.22M | $ -100.19M |
| Total Liabilities | $ 123.36M | $ 126.53M | $ 130.60M | $ 154.70M | $ 125.63M |
| Stockholders' Equity | $ 292.54M | $ 422.18M | $ 512.23M | $ 666.88M | $ 925.20M |
| Cash Flow | |||||
| Free Cash Flow | $ -149.63M | $ -200.99M | $ -239.25M | $ -225.71M | $ -206.26M |
| Operating Cash Flow | $ -149.25M | $ -200.30M | $ -237.73M | $ -220.52M | $ -184.81M |
| Investing Cash Flow | $ 95.56M | $ 75.69M | $ 163.29M | $ 106.16M | $ 163.66M |
| Financing Cash Flow | $ 30.16M | $ 116.67M | $ 95.69M | $ 2.95M | $ 11.96M |